ResMed (RMD) Tops Q3 EPS by 25c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ResMed (RMD:AU) (RMD) PT Raised to AUD22.60 at JPMorgan
April 28, 2020 1:13 PM EDTJPMorgan raised its price target on ResMed (RMD:AU) to AUD22.60 (from AUD22.00) while maintaining a Neutral rating.
Analyst lowers price target on (NYSE: RMD) to US$145 from US$150. Maintains Neutral rating.
... More